ClinicalTrials.gg
RecruitingNCT07335913Updated Mar 3, 2026

Phase 1 Study of SBS-147 in Healthy Adults

A Phase 1 interventional study of SBS-147 and Placebo in Pain Acute and Pain, sponsored by Sparian Biosciences, Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Sparian Biosciences, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Planned enrollment
164th of 322
80 · median 86
Started
2026
with 13 others
Phase 1
27 of 353
3 open now
Primary completion
2027-01
later than 21 of 54 live
Registered
337th of 353
by date

Among the 353 studies in Acute Pain with a site in United States, this one is the 164th largest by planned enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2026, is one of 27 in phase 1, reaches primary completion later than 21 of the 54 other live ones, and was the 337th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

This study is part of the HEAL Initiative supported by the NIH.

The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147.

Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results.

The study includes two parts:

Single-Dose Group, where Participants receive SBS-147 or placebo one time.

Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Read the detailed description

The goal of this clinical trial is to learn about the safety of SBS-147. The main questions it aims to answer are:

What medical problems do participants have when taking SBS-147? Researchers will compare SBS-147 to a placebo (a look-alike substance that contains no drug) to see if SBS-147 works to treat acute pain.

Participants in the single ascending dose portion will:

Take SBS-147 or a placebo one time during the study Stay confined to the clinic for a period of 5 days and undergo tests, blood draws, and questionnaires.

Complete an end of study visit on Day 8

Participants in the multiple ascending dose portion will:

Take SBS-147 or a placebo one time per day or twice a day for 7 days Stay confined to the clinic for a period of 10 days and undergo tests, blood draws, and questionnaires.

Complete an end of study visit on Day 14

03

Conditions studied

  • Pain Acute
  • Pain

Keywords

  • Arylepoxamide
  • AEAr Agonist
  • 6TM
  • Tolerability
  • Safety
  • SBS-147
  • SBS147
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form (ICF)
  2. Healthy adult male or female, aged 18 to 55 years, inclusive, at Screening
  3. (BMI) within 18.0 kg/m2 to 32.0 kg/m2 inclusively
  4. Minimum body weight of at least 50.0 kg at Screening
  5. Stated willingness to comply with all study procedures and availability for the duration of the study
  6. Females of
  7. Healthy, as determined by protocol requirements
  8. Non- or ex-smoker for at least 90 days prior to Screening
  9. Participant is able and willing to comply with all study protocol procedures and requirements

Exclusion criteria

Exclusion Criteria:

  1. Female who is lactating at Screening
  2. Female who is pregnant
  3. History of significant reactions (like angioedema) to any drugs
  4. Presence or history of significant surgery that may affect drug bioavailability
  5. History of significant CV, pulmonary, hematologic, neurologic, psychiatric, endocrine, infectious, or immunologic disease
  6. Meet 5 (DSM-5) criteria for lifetime or current substance use disorder for any psychoactive substances other than nicotine or caffeine
  7. Showing suicidal tendency as per the C-SSRS administered at screening and clinic admission
  8. Any illness in the 28 days prior to the first study drug administration
  9. Use of any prescription drugs in the 28 days or 5 half-lives, whichever is longer, prior to Screening and until the end of the study, that in the opinion of an Investigator would put into question the status of the participant as healthy
  10. Use of opioids, hypnotics, and/or sedatives in the last 30 days prior to screening
  11. Routine or chronic use of acetaminophen or nonsteroidal anti-inflammatory drugs for more than 7 of the 20 days during the screening period.
  12. Use of St. John's Wort in the 28 days prior to Screening
  13. Use of any herbal supplements (including Kratom) the 14 days prior to Screening
  14. Intake of an Product (IP) in the 30 days prior to Screening
  15. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration
  16. Positive screening results to Ag/Ab combo, surface antigen or virus Ab tests
  17. Any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of an Investigator and based on clinical judgment, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
  18. Donation of plasma in the 7 days prior to Screening
  19. Donation of 1 unit of blood to American Red Cross or equivalent organization or donation of over 500 mL of blood in the 56 days prior to Screening
  20. Inclusion in a previous cohort for this clinical study
  21. Supine pulse rate less than 45 beats per minute (bpm) or more than 100 bpm at the screening visit
  22. Supine systolic blood pressure \< 90 or > 140 mmHg or diastolic blood pressure \< 40 or > 90 mmHg at the Screening visit
  23. Oxygen saturation (SpO2) below 95% at the Screening visit
  24. Presence of out-of-range cardiac interval on the at screening or other clinically significant ECG abnormalities, unless deemed non-significant by an Investigator
  25. History of risk factors for Torsades de Pointes, including unexplained syncope, known long syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalaemia, hypercalcaemia, or hypomagnesaemia
  26. Family history of long QT syndrome or Brugada syndrome
  27. History of fainting
  28. Family history of sudden cardiac death or significant heart disease
  29. Known presence or history of gastroesophageal reflux or hiatal hernia
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose

    Single dose of SBS-147 or a placebo given during trial

    Drug: SBS-147 · Drug: Placebo

  • Experimental
    Multiple Ascending Dose

    SBS-147 or placebo given repeatedly over several days during the trial

    Drug: SBS-147 · Drug: Placebo

Interventions

  • DrugSBS-147

    Experimental therapeutic

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    To assess the number of treatment emergent adverse events experienced in participants after a single dose of SBS-147

    Time frame: 8 days

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at ascending doses

    Assess the number of treatment emergent adverse events experienced by participants of SBS-147 after multiple dose oral administration in healthy adults.

    Time frame: 14 days

Secondary outcomes

  1. Relative plasma exposure of SBS-1000 compared with SBS-147 (SAD)

    Geometric mean ratios (SBS-1000 / SBS-147) for Cmax and AUC

    Time frame: 0-12 hours, 0-24 hours, and extrapolated to infinity after dosing

  2. Plasma pharmacokinetics of SBS-1000 and SBS-147 following multiple ascending doses

    Plasma concentrations of SBS-1000 and SBS-147 will be analyzed using noncompartmental methods to characterize single-dose and steady-state pharmacokinetics.

    Time frame: Day 1 (single-dose PK) and Day 7 at steady state over the dosing interval (τ)

07

Study locations

1 of 1 sites recruiting
  • AltaSciences, Inc
    Cypress, California 90630, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 33 phase 1 interventional studies under Acute Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 17. This study's planned 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 13, 2026
StartActual
Jan 8, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Feb 28, 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335913
Lead sponsor
Sparian Biosciences, Inc
Collaborators
National Institutes of Health (NIH), Altasciences Company Inc.
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Jan 8, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Oscar McClyde
Contact
omcclyde@altasciences.com
913-696-1601
Jeff Reich, MD
study director · Sparian Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion